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0959-8049/ª 2019 Elsevier Ltd. All righAbstract Introduction: Nonesmall-cell lung cancer (NSCLC) guidelines advise to screen
stage III NSCLC patients for brain metastases (BMs), preferably by magnetic resonance im-
aging (MRI) or when contraindicated or not accessible a dedicated contrast enhanced
ecomputed tomography (dCE-CT), which can be incorporated in the staging 18Fluodeoxoglu-
coseepositron emission tomography (18FDG-PET-CE-CT). In daily practice, often a dCE-CT
is performed instead of a MRI. The aim of the current study is to evaluate the additive value of
MRI after dCE-CT, incorporated in the 18FDG-PET-CE-CT.
Patients and methods: It is an observational prospective multicentre study (NTR3628). Inclu-
sion criteria included stage III NSCLC patients with a dCE-CT of the brain incorporated in
the 18FDG-PET and an additional MRI of the brain. Primary end-point is percentage of pa-
tients with BM on MRI without suspect lesions on dCE-CT. Secondary end-points areonary Diseases, GROW-School for Oncology and Developmental Biology, Maastricht University Medical
stricht, the Netherlands. Fax: þ31(0)43-3871318.
c.nl (L.E.L. Hendriks).
7
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J. Schoenmaekers et al. / European Journal of Cancer 115 (2019) 88e96 89percentage of patients with BM on dCE-CT and percentage of patients with BM  1 year of a
negative staging MRI.
Results: Sixteen (7%) patients with extracranial stage III had BM on dCE-CT and were
excluded. One hundred forty-nine patients were enrolled. 7/149 (4.7%) had BM on MRI
without suspect lesions on dCE-CT. One hundred eighteen patients had a follow-up of at least
1 year (four with BM on baseline MRI); eight of the remaining 114 (7%) patients developed
BM  1 year after a negative staging brain MRI.
Conclusion: Although in 7% of otherwise stage III NSCLC patients, BMs were detected on
staging dCE-CT, MRI brain detected BMs in an additional 4.7%, which we consider clinically
relevant. Within 1 year after a negative staging MRI, 7% developed BM.
ª 2019 Elsevier Ltd. All rights reserved.1. Introduction
Brain metastases (BMs) frequently occur in nonesmall-
cell lung cancer (NSCLC) patients, and risk increases
with stage. About 20% of stage III NSCLC, patients
have BM at baseline [1,2]. In all guidelines, it is advised
to screen stage III NSCLC patients as usually only those
without BM are eligible for intense combined modality
treatment [3e6]. The preferred brain imaging modality
is post contrast magnetic resonance imaging (MRI) or,
when contra-indicated, a dedicated contrast enhan-
cedecomputed tomography (dCE-CT) [3e6]. However,
access to MRI can be problematic, and there are also
some contra-indications for MRI (e.g. some pace-
makers, claustrophobia). In a United Kingdom (UK)
survey (2014) on brain imaging in neurologically
asymptomatic lung cancer patients, dCE-CT was
preferred above MRI, presumably because of lack of
access to MRI [7]. Another recently published European
survey (462 responders) also showed that only 52.2%
used MRI to screen for BMs. Moreover, only 63%
screened stage III NSCLC patients [8].
Furthermore, in all patients eligible for therapy with
curative intent, a whole body 18F-deoxyglucose-positron
emission tomography (18FDG-PET) is advised to
exclude distant metastases [3e5,9]. An 18FDG-PET is
performed with a non-diagnostic low-dose CT (LD-CT)
for attenuation correction, but a dCE-CT of the thorax,
upper abdomen and brain can be added [10]. 18FDG-
PET with a LD-CT is not suitable for BMs detection
[11e15]. From older studies (patient inclusions from
1980 up to 2004), including patients with mixed tumour
types and tumour stages, it is known that MRI of the
brain is more sensitive than dCE-CT in detecting pres-
ence and especially number of metastases [16e20].
However, it has not been shown; this is still the case in
the setting of screening for asymptomatic BMs in
already 18FDG-PET staged stage III NSCLC patients.
In recent years, the techniques concerning CT as well as
MRI have improved. In a retrospective study (N Z 77)with these up-to date MRI and CT protocols
(2008e2011), no additional BMs were found on MRI
after 18FDG-PET-CT with dedicated brain CE-CT in
stage III NSCLC patients. In contrast, 16% of those
with only a LD-CT were diagnosed with BM on MRI
[15]. BM remain a serious issue as in this retrospective
study, 13% with a negative staging brain MRI developed
symptomatic BM within a year of NSCLC diagnosis
[15]. A similar percentage of BM development was
found in another large retrospective series (N Z 838) of
stage III NSCLC patients that underwent baseline brain
imaging [21]. When dCE-CT of the brain performed in
the same setting as 18FDG-PET-CT could lead to the
same yield of BM detection as 18FDG-PET-LD-CT with
a separate brain MRI, a substantial gain in time and
resources could be expected. In this prospective obser-
vational multicentre study, we evaluated whether there
is a clinically relevant additive value of MRI to dedi-
cated brain CE-CT (performed as part of the 18FDG-
PET-CE-CT) in detecting asymptomatic BM in stage III
NSCLC patients when both are performed in standard
work-up.
2. Materials and methods
2.1. Study design and patient selection
This was a prospective, multicentre (N Z 3) study in the
Netherlands. In the participating hospitals, it is routine
practice to perform a dCE-CT of the brain and chest
together with the 18FDG-PET-CT, when no recent
diagnostic chest CE-CT is available. In addition, stan-
dard practice is to perform brain MRI in all stage III
NSCLC patients eligible for therapy with curative
intent. Patients were included by prospectively screening
the agenda of the weekly multidisciplinary lung tumour
boards of the participating hospitals. As according to
Dutch guidelines, all lung cancer patients must be dis-
cussed in these tumour boards, no patients are missed.
All stage III (7th tumour-node-metastasis [TNM]
J. Schoenmaekers et al. / European Journal of Cancer 115 (2019) 88e9690edition) NSCLC patients scheduled for treatment with
curative intent were included. For inclusion in this
study, stage III was based on 18FDG-PET-CE-CT with
dCE-CT of the brain, i.e. without taking into account
the results of MRI.
In addition, the number of patients with asymptom-
atic BM found on 18FDG-PET-CE-CT in otherwise
stage III NSCLC was scored. The exclusion criteria
included a second primary cancer within 2 years of stage
III NSCLC diagnosis (except recurring NSCLC eligible
for treatment with curative intent, cervical cancer in situ
or non-melanoma skin cancer), no dCE-CT of the brain
during the 18FDG-PET scan and no brain MRI and
mixed histology (i.e. SCLC and NSCLC). Initially, the
aim was also to exclude patients with a brain MRI
performed more than 3 weeks after the 18FDG-PET-CE-
CT as it could not be excluded that BM not visible on
dCE-CT of the brain became visible on MRI in a longer
time period. However, during the study, it proved to be
very difficult to obtain the MRI within this time, so all
patients fulfilling the other criteria were included, irre-
spective of MRI timing.
The MUMCþethics committee stated that patient
informed consent was not mandatory according to the
Dutch law ‘Medical Research (human subjects) Act’ as
both 18FDG-PET-CE-CT and MRI are standard
workup according to the Dutch NSCLC guideline, and
work-up and treatment were not influenced by the study
(METC 12-4-126). The study was registered on the
Dutch Trial Registry (NTR3628). Because of the
observational study design, patients who already had
had a CE-CT of the chest did not undergo a CE-CT
combined with the 18FDG-PET scan, as standard
practice was to perform only a LD-CT combined with
the 18FDG-PET scan. If not already performed, brain
MRIs were advised during the tumour boards, but the
decision to perform a brain MRI was according to the
treating physician.2.2. Outcomes
Primary end-point was the percentage of patients with
stage III NSCLC (based on 18FDG-PET-CE-CT) diag-
nosed with BMs on MRI, but without suspect lesions on
the dCE-CT of the brain. Secondary end-points were as
follows: (1) the percentage of patients in which asymp-
tomatic BM were found on 18FDG-PET-CE-CT and (2)
the percentage of patients developing symptomatic BM
within 1 year after a negative brain MRI.
The following data were collected: age; gender;
World Health Organisation performance score; smoking
status; date of stage III NSCLC diagnosis; date of
18FDG-PET-CE-CT and brain MRI; histology; whether
molecular testing was performed; TNM; details on
therapy modality (chemotherapy cycles, delivered radi-
ation dose and whether treatment was completed) anddevelopment of BM during follow-up (date, number,
treatment modality).
2.3. MRI and dCE-CT of the brain protocols
(during 18FDG-PET-CE-CT)
See supplemental data S1.
2.4. Statistical analyses
2.4.1. Sample size calculation
The primary end-point for this study was the percentage
of patients diagnosed with BMs on MRI, but without
suspect lesions on the dCE-CT of the brain. After
intercollegial discussion, difference of more than 2% was
considered clinically relevant. With an expected differ-
ence of 2% and a one-sided 95% confidence interval
(95% CI) not exceeding 4%, a total of 118 18FDG-PET-
CE-CT and brain MRI staged patients were needed to
calculate a one-sided 95% CI around 2% that excluded
the 4% threshold, given these assumptions. After 118
patients were included, we decided to continue including
patients during the 1 year follow-up period of the first
118 patients to have more solid data for the primary
end-point.
Statistical analysis was performed with SPSS (version
23; SPSS Inc., Chicago, IL). The secondary end-points
and baseline characteristics were analysed using stan-
dard descriptive statistics.
3. Results
All NSCLC patients presented at the tumour boards
from December 2012 until October 2017 were screened
for eligibility. Three hundred thirty-eight consecutive
patients had extracranial stage III NSCLC based on
18FDG-PET. In 118/338 patients (35%), no dedicated
brain CE-CT was performed together with the staging
FDG-PET, 62 out of these 118 (52%) patients had only
a LD-CT for attenuation correction, and after central
revision of the CE-CTs of the brain, 56/118 (47%) had a
CE-CT but without dedicated brain imaging protocol
(i.e. wrong field of view and/or hands above the head).
Seventy-one (32%) of the remaining 220 patients were
excluded because of asymptomatic BMs on dCE-CT of
the brain (N Z 16, 7%), second primary (N Z 11, 5%)
or no brain MRI (N Z 44, 20%). As a result, 149 pa-
tients were included, of whom 118 had a follow-up of at
least 1 year (Fig. 1). Baseline characteristics are sum-
marised in Table 1.
Median time (range) between 18FDG-PET-CE-CT
and MRI was 2.4 (0.0e8.1) weeks. In 24.7%, time from
18FDG-PET to MRI was more than 3 weeks.
In 7/149 (4.7%) patients, BMs were detected on MRI
despite no suspect brain lesions on dCE-CT. In retro-
spect, after central review of all the imaging, in one of
these seven patients, a solitary BM could be identified
Fig. 1. Consort diagram. CE-CT, contrast enhancedecomputer tomography; MRI, magnetic resonance imaging; NSCLC, nonesmall-cell
lung cancer; 18FDG-PET, 18F-deoxyglucoseepositron emission tomography; LD-CT, low-dose CT.
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seven patients are summarised in Table 2.
118/149 patients had a follow-up period of at least
1year. Treatment characteristics of these 118 patients
are in Table 3. 4/118 had already baseline BMs on MRI
(3.4%).
8/114 (7%) patients developed symptomatic BM
within a year of a negative staging brain MRI. All but
one of these patients completed the treatment for their
stage III disease (six concurrent chemoradiation, one
radical radiotherapy only). Characteristics of these eight
patients are summarised in Table 4.
4. Discussion
In this prospective observational multicentre study, with
up-to-date staging and imaging protocols, we evaluated
whether brain MRI was superior to 18FDG-PET-CE-
CT with dCE-CT of the brain in detecting asymptomatic
BM in otherwise stage III NSCLC patients. We defined
a difference of more than 2% clinically relevant, as after
multidisciplinary discussion, we felt that missing ahigher percentage of BM would not be desirable as a
BM diagnosis changes the treatment plan (i.e. either
radically treat the BM or when not possible withhold
patients from an intense multimodality treatment). In
our study, brain MRI was superior to dCE-CT of the
brain as an additional 4.7% of patients were diagnosed
with BM on MRI. This study also shows that adequate
brain imaging is necessary in this patient population, as
despite the finding that 16 patients (7%) were diagnosed
with asymptomatic BM on dCE-CT of the brain, brain
MRI detects BM in an additional 4.7%. The total per-
centage of asymptomatic BM detected is comparable to
previous studies [1,15].
In the participating hospitals, performing a MRI
brain within a reasonable time period after 18FDG-PET
proved to be difficult, as in 24.7% the time from 18FDG-
PET to MRI was more than 3 weeks. This is not a
problem unique for the participating hospitals, as in a
United Kingdom survey (2014), CE-CT was preferred
above MRI, presumably because of lack of access to
MRI [7]. However, delay from 18FDG-PET-CE-CT to
MRI with subsequent growth of a microscopic BM does
Table 1
Baseline characteristics.
Patient characteristic Group 1 Group 2 Total
(N Z 118) (N Z 31) (N Z 149)
Median age (years) 68 62 68
WHO PS, N (%)
0 38 (32.2) 14 (45.2) 52 (34.9)
1 60 (50.8) 13 (42) 73 (49)
2 14 (11.9) 3 (9.7) 17 (11.4)
3 2 (2) 1 (3.2) 3 (2)
4 0 (0) 0 (0) 0 (0)
Unknown 4 (3.4) 0 (0) 4 (2.7)
Smoking status, N (%)
Current 60 (50.8) 17 (54.8) 77 (51.7)
Former 54 (45.8) 12 (38.7) 66 (44.3)
Never 2 (1.7) 1 (3.2) 3 (2)
Unknown 2 (1.7) 1 (3.2) 3 (2)
cTstage, N (%)
o/x 3 (2.5) 2 (6.5) 5 (3.4)
1a 4 (3.4) 1 (3.2) 5 (3.4)
1b 8 (6.8) 1 (3.2) 9 (6)
2a 24 (20.3) 1 (3.2) 25 (16.8)
2b 12 (10.2) 1 (3.2) 13 (8.7)
3 19 (16.1) 4 (12.9) 23 (15.4)
4 48 (40.7) 21 (67.7) 69 (46.3)
cNstage, N(%)
o/x 12 (10.2) 9 (29) 21 (14.1)
1 5 (4.2) 3 (9.7) 8 (5.4)
2 72 (61) 15 (48.4) 87 (58.4)
3 29 (24.6) 4 (13) 33 (22.1)
cTNM (7th edition)
IIIA 62 (52.5) 16 (51.6) 78 (52.3)
IIIB 52 (44.1) 12 (38.7) 64 (43)
IV (brain metastases diagnosed
on baseline brain MRI)
4 (3.4) 3 (9.7) 7 (4.7)
Histology, N (%)
Adenocarcinoma 56 (47.5) 11(35.5) 67 (45)
Squamous cell carcinoma 46 (39) 11 (35.5) 57 (38.3)
Large cell carcinoma 1 (0.8) 3 (9.7) 4 (2.7)
NOS 13 (11) 6 (19.4) 19 (12.8)
LCNEC 2 (1.7) 0 (0) 2 (1.3)
Molecular analysis, N (%)
Not performed 62 (52.5) 23 (74.2) 85 (57)
Performeda
EGFR/KRAS wt, ALK- 28 (50) 5 (62.5) 33 (51.6)
EGFR mutation 1 (1.8) 0 (0) 1 (1.6)
KRAS mutation 25 (44.6) 3 (37.5) 28 (43.8)
ALK translocation 1 (1.8) 0 (0) 1 (1.6)
Other 1 (1.8) 0 1 (1.6)
N, number; WHO PS, World Health Organisation Performance status;
T, tumour; N, node; MRI, magnetic resonance imaging; NOS, not
otherwise specified; LCNEC, large cell neuroendocrine carcinoma;
EGFR, epidermal growth factor receptor; KRAS, Kirsten Rat Sar-
coma viral antigen; ALK, anaplastic lymphoma kinase; wt: wildtype.
Group 1: first cohort of included patients with year of follow up;
Group 2: additional cohort of included patients during the year follow
up of first group.
a Percentage computed only for those with known molecular
analysis.
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MRI for the seven patients in the present study, as
median time (range) to MRI was 2.7 (0.4e6.4) weeks.
MRI can cause a delay in the workup of stage III
NSCLC which is not desirable as, for example,according to the Dutch SONCOS document (SONCOS:
‘Foundation for Oncological Collaboration’) treatment
has to start within 5 weeks of diagnosis [22]. Our results
stress the importance of adequate screening for BM in
this patient population and that a brain MRI is neces-
sary, even after a dCE-CT of the brain (which can, as in
our trial, be incorporated in the 18FDG-PET or can be
performed after a 18FDG-PET). Screening with MRI
should be more accessible and better integrated in the
standard work-up as for example in the UK and Eu-
ropean surveys, not all physicians screened their stage
III patients and not all use MRI [7,8]. Even in our
prospective study, in which MRIs, if not already per-
formed, were advised during the tumour boards, not all
patients without contraindications underwent MRI of
the brain. In this observational study, no real-time check
was performed to evaluate whether this advice was
followed.
Detecting BM in this patient population is important
as combined modality treatment is intense with a high
incidence of adverse events [23,24]. Despite this intense
treatment, the 5-year overall survival is only around
30% in recent series [25e27]. Most patients diagnosed
with BM will not be eligible for this intensive treatment
regimen, and some will be diagnosed with single or
oligo-BM, potentially amenable to treatment with
curative intent (surgery or radical radiotherapy) [28].
Our findings in stage III NSCLC also reinforce the
recommendations recently published in the European
Respiratory Journal to screen for BM in this patient
population, and we show that MRI is more sensitive
than dCE-CT [29,30]. The National Institute for health
and care excellence in the UK recently updated their
brain imaging advise, and MRI is now explicitly advised
in the staging work-up of stage III NSCLC [6].
Another important issue is that 7.5e15% of stage III
NSCLC patients with negative baseline brain imaging
will develop (mostly symptomatic) BM within a year of
NSCLC diagnosis [15,31]. With longer follow-up, this
percentage increases further: in the NVALT-11/
DLCRG-02 trial for example, which mandated base-
line brain imaging with MRI or CT, 27.2% of patients
developed symptomatic BM within 2 years after treat-
ment with radical intent [32]. It is not known whether
these metastases were already present at initial stage III
diagnosis and were not detected by brain imaging or
that these were newly developing metastases. Maybe
some could have been detected with more sensitive
MRI-techniques (higher contrast dose or higher Tesla),
but this can also increase the possibility for false positive
findings [33,34].
Regular follow-up brain imaging in high-risk patients
is also an option to detect BMs when they are possibly
still eligible for therapy with radical intent, but this is
not recommended in NSCLC guidelines [3e5,9]. Known
risk factors (adenocarcinoma, higher nodal stage and
female gender) alone cannot predict reliably enough
Table 2
Patient characteristics of seven patients with BMs on MRI despite no suspect lesions on dCE-CT of the brain.
Patient
characteristic
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Gender (M/F) F M M M M M F
Age (years) 60 62 65 48 67 65 62
WHO PS score 0 1 1 1 1 0 0
cTstage 4 1b 3 3 2a 3 4
cNstage 3 2 1 2 2 2 2
Histology Adeno Adeno Squamous Squamous Adeno Squamous Adeno
Molecular
analysis
None KRAS Not performed None None Not performed None
Time between
dCE-CT
and MRI
(weeks)
1.86 6.43 0.43 1.29 5.86 2.29 1.00
Thoracic
treatment
Chemotherapy
(cisplatin/
pemetrexed)
Chemotherapy
(Carboplatin/
pemetrexed)
Neoadjuvant CRT
(cisplatin/etoposide)
þ Lobectomy
Sequential CRT
(gemcitabin/
cisplatin)
Sequential CRT,
after 1 cycle
progressive disease
Concurrent CRT
(Cisplatin/
etoposide)
Concurrent
CRT (cisplatin/
etoposide)
BMs, brain metastases; MRI, magnetic resonance imaging; CE-CT, contrast enhancedecomputer tomography; WHO PS, World Health Orga-
nisation performance status; F, female; M, male; T, tumour; N, node; KRAS, Kirsten Rat Sarcoma viral antigen; dCE-CT, dedicated contrast
enhancedecomputed tomography; CRT, chemoradiation.
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(N Z 317 and N Z 527), single nucleotide poly-
morphisms in the PI3K-PTEN-AKT-mTOR pathway
and microRNAs, respectively, were associated with the
development of BMs in the follow-up [35,36]. However,
serum tumour markers such as CEA, CYFRA21-1 and
CA-125 were not associated with the development of
BMs [37]. Future studies with larger samples are
necessary to validate these findings.Table 3
Treatment characteristics of patients with a minimum follow-up of 1
year.
Treatment characteristics Group 1
N Z 118
Treatment modality, N (%)
Concurrent CRT 75 (61.9)
Sequential CRT 26 (22)
Radical radiotherapy alone 2 (1.7)
Palliative chemotherapya 2 (1.7)
Surgeryb 9 (7.6)
BSCa 4 (3.4)
Radical treatment completedc,
N (%)
Yes 92 (82.1)
No 20 (17.9)
Cycles chemotherapy when
treated with CRT, N (%)
1 9 (8.9)
2 6 (5.9)
3 82 (81.2)
4 4 (4)
Dose radiotherapy (Gy)
Mean  SD 66  15
CRT, chemoradiotherapy; BSC, best supportive care.
a Radical treatment planned, but cancelled because of rapidly dete-
riorating physical condition.
b As part of multimodality treatment.
c For those who started radical intent therapy (N Z 112).Prophylactic cranial irradiation (PCI) to prevent the
development of symptomatic BM is also an option. The
randomised phase III NVALT11/DLCROG-02 study
already mentioned above showed that PCI significantly
decreases the proportion of patients developing symp-
tomatic BM at 2 years after completion of chemo-
radiation (7.0% versus 27.2%), but at the cost of an
increase in low-grade toxicity and without an improve-
ment in overall survival [32].
Finally, immunotherapy could also have a role in
reducing the incidence of BM after radical treatment, as
shown in the randomised phase III PACIFIC trial
(NCT02125461), evaluating adjuvant durvalumab
(programmed death ligand 1 antibody) versus placebo in
stage III NSCLC treated with concurrent chemo-
radiation. After a median follow-up of 25.6 months
(from randomisation after completion of chemo-
radiation), the percentage of patients that developed
BM was lower for durvalumab than for placebo (6.3%
versus 11.8%) [38]. However, the percentage of BMs
found is surprisingly low in this trial, as even the 11.8%
in the placebo arm is approximately half of the per-
centage found in the comparator arm of contemporary
stage III NSCLC PCI trials with baseline brain imaging
(reviewed by Witlox et al.) [39]. Furthermore, in the
PACIFIC trial baseline brain imaging was not manda-
tory, which should have resulted in a higher percentage
of BM diagnosis during follow-up, as asymptomatic BM
at baseline could have become symptomatic.
A possible limitation of our trial is the short follow-
up, making comparison with other trials with longer
follow-up difficult. However, our primary aim was to
compare baseline dCE-CT and MRI brain, and one of
our secondary aims was the percentage of patients with
BM within a year of a negative brain MRI. Both these
end-points are not influenced by the short follow-up.
Table 4
Patient characteristics of eight patients who developed BM within a year after negative baseline MRI.
Patient
characteristic
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Gender (M/F) M F F M M F M F
Age (years) 67 57 51 69 70 60 74 70
WHO PS score 3 1 0 1 0 2 1 1
cTstage T2a T1b T2a T3 T2a T4 T3 T2b
cNstage N2 N2 N3 N2 N2 N2 N3 N2
TNM stage
(7th edition)
IIIA IIIA IIIB IIIA IIIa IIIB IIIa IIIA
Histology Adeno
carcinoma
Adeno
carcinoma
Adeno
carcinoma
Adeno
carcinoma
Adeno
carcinoma
Squamous
cell carcinoma
NOS Adeno
carcinoma
Molecular
analysis
None None KRAS KRAS KRAS KRAS None None
Treatment
for stage
III NSCLC
Radical
RTx
(66Gy)
Concurrent
chemoradiation
(carbo/eto)
Concurrent
chemoradiation
(cis/eto)
Concurrent
chemoradiation
(cis/eto)
Concurrent
chemoradiation
(cis/eto)
Concurrent
chemoradiation
(cis/eto)
Concurrent
chemoradiation
(cis/eto)
Sequential
chemoradiation
(cis/eto)
Also
extracranial
progression
No No Yes No Yes Yes Yes Yes
M, male; F, female; WHO PS, World Health Organisation performance status; c, clinical; T, tumour; N, node; M, metastases; KRAS, Kirsten Rat
Sarcoma viral antigen; RTx, radiotherapy; Gy, Gray; carbo, carboplatin; eto, etoposide; cis, cisplatin; NOS, not otherwise specified.
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suboptimal brain CTs, make extrapolation to patients
not screened with a dCE-CT difficult. However, we
think it is also a strong point of our study that all
included patients underwent the same, dedicated brain
CT, and even with this dedicated CT-protocol, MRI
detects asymptomatic BMs in more patients.
In conclusion, screening for BM is mandatory in the
work-up of stage III NSCLC patients, and MRI is su-
perior to a dedicated brain CE-CT. As the brain is a
common site of relapse, prediction of BM development
and prevention of BM should be the focus of clinical
trials.
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